Abbott's Q3 Net Earnings Flat Amid Strong Device Sales, COVID Test Slump

TL;DR

**ABT's flat Q3 net earnings are a non-event; strong Medical Device sales and a significant nine-month earnings jump confirm a solid long-term growth trajectory, making it a buy.**

AI Summary

Abbott Laboratories reported a slight decrease in net earnings for the three months ended September 30, 2025, at $1,644 million, compared to $1,646 million in the same period of 2024. However, net sales increased by 6.9% to $11,369 million from $10,635 million year-over-year. For the nine months ended September 30, 2025, net earnings rose significantly to $4,748 million from $4,173 million in 2024, an increase of 13.8%. Total net sales for the nine-month period also grew by 6.1% to $32,869 million from $30,976 million. The Medical Devices segment was a strong performer, with sales increasing by $701 million to $5,448 million in Q3 2025, driven by Diabetes Care, which saw sales jump by $332 million to $2,057 million. Conversely, COVID-19 testing-related sales continued their decline, falling to $69 million in Q3 2025 from $265 million in Q3 2024, representing a 74% decrease. Operating earnings for the nine months ended September 30, 2025, increased by $888 million to $5,802 million, reflecting improved operational efficiency despite higher total operating costs and expenses of $27,067 million. The company's strategic outlook includes continued investment in R&D, which increased to $2,207 million for the nine-month period, and managing foreign currency translation adjustments, which resulted in a $1,414 million gain for the nine months ended September 30, 2025.

Why It Matters

Abbott's mixed Q3 results, with flat net earnings but robust sales growth in Medical Devices, signal a successful pivot away from declining COVID-19 testing revenue. This diversification is crucial for investors seeking stable long-term growth in the competitive healthcare sector. Employees in the Medical Devices and Nutritional Products segments may see increased opportunities, while those in Diagnostics, particularly COVID-19 related roles, might face adjustments. Customers benefit from continued innovation in diabetes care and other medical technologies. The broader market will watch how Abbott's strategic investments in R&D and acquisitions, like the $85 million spent on businesses and technologies, translate into sustained competitive advantage against rivals like Medtronic and Dexcom.

Risk Assessment

Risk Level: medium — The company faces a significant decline in COVID-19 testing-related sales, dropping from $571 million in the first nine months of 2024 to $208 million in the same period of 2025, a 63.5% decrease. This revenue stream, once substantial, is rapidly diminishing. Additionally, foreign currency translation adjustments can introduce volatility, as evidenced by a $(136) million loss in Q3 2025 compared to a $497 million gain in Q3 2024, impacting comprehensive income.

Analyst Insight

Investors should maintain a bullish stance on ABT, focusing on its strong Medical Devices segment growth, particularly in Diabetes Care, which saw sales increase by $923 million for the nine months ended September 30, 2025. The decline in COVID-19 testing revenue is largely offset by other segments, and the company's increased R&D spending to $2,207 million for the nine-month period suggests future innovation and market leadership.

Financial Highlights

revenue

$11,369M

net Income

$1,644M

eps

$0.94

revenue Growth

+6.9%

Revenue Breakdown

Key Numbers

• $11,369M — Net Sales (Q3 2025) (Increased from $10,635M in Q3 2024, a 6.9% rise.)
• $1,644M — Net Earnings (Q3 2025) (Slightly decreased from $1,646M in Q3 2024.)
• $32,869M — Net Sales (YTD Sept 2025) (Increased from $30,976M in YTD Sept 2024, a 6.1% rise.)
• $4,748M — Net Earnings (YTD Sept 2025) (Increased from $4,173M in YTD Sept 2024, a 13.8% rise.)
• $69M — COVID-19 Testing Sales (Q3 2025) (Decreased from $265M in Q3 2024, a 74% decline.)
• $2,057M — Diabetes Care Sales (Q3 2025) (Increased from $1,725M in Q3 2024, a 19.2% rise.)
• $5,448M — Medical Devices Sales (Q3 2025) (Increased from $4,747M in Q3 2024, a 14.8% rise.)
• $2,207M — Research and Development (YTD Sept 2025) (Increased from $2,095M in YTD Sept 2024, a 5.3% rise.)
• $0.94 — Diluted EPS (Q3 2025) (Remained flat compared to Q3 2024.)
• $2.70 — Diluted EPS (YTD Sept 2025) (Increased from $2.38 in YTD Sept 2024, a 13.4% rise.)

Key Players & Entities

• ABBOTT LABORATORIES (company) — registrant in 10-Q filing
• New York Stock Exchange (regulator) — exchange where ABT common shares are registered
• FASB (regulator) — Financial Accounting Standards Board
• Medtronic (company) — competitor in medical devices
• Dexcom (company) — competitor in diabetes care
• Illinois Corporation (company) — Abbott's legal structure
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Declining COVID-19 Testing Revenue [medium — market]: COVID-19 testing-related sales have significantly declined, falling to $69 million in Q3 2025 from $265 million in Q3 2024, a 74% decrease. This trend indicates a substantial reduction in a previously significant revenue stream.
• Increased Operating Costs [medium — operational]: Total operating costs and expenses increased to $27,067 million for the nine months ended September 30, 2025. While operating earnings grew, this highlights the need for continued focus on cost management to maintain or improve margins.
• Global Regulatory Environment [high — regulatory]: As a global healthcare company, Abbott Laboratories is subject to complex and evolving regulatory requirements in numerous jurisdictions. Changes in regulations related to medical devices, pharmaceuticals, and diagnostics could impact product approvals, market access, and compliance costs.
• Foreign Currency Fluctuations [medium — financial]: The company experienced a $1,414 million gain from foreign currency translation adjustments for the nine months ended September 30, 2025. While beneficial in this period, significant adverse currency movements could negatively impact reported earnings and sales.

Industry Context

The healthcare industry, particularly in medical devices and diagnostics, is characterized by rapid innovation, significant R&D investment, and a complex regulatory landscape. Companies like Abbott Laboratories compete on product efficacy, technological advancement, and market access. Trends include a growing demand for personalized medicine, digital health solutions, and cost-effective diagnostics, alongside increasing scrutiny on pricing and regulatory compliance.

Regulatory Implications

Abbott Laboratories operates under stringent global regulatory frameworks for medical devices, diagnostics, and pharmaceuticals. Compliance with FDA, EMA, and other international bodies is critical for product approval, manufacturing, and marketing. Any changes in regulatory requirements or enforcement actions could significantly impact operations and financial performance.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Glossary

Net Sales

The total revenue generated from the sale of goods and services after deducting returns, allowances, and discounts. (Indicates the company's top-line performance and market demand for its products.)

Net Earnings

The profit remaining after all expenses, including taxes and interest, have been deducted from total revenue. (Represents the company's profitability.)

Diluted EPS

Earnings per share calculated by dividing net income by the weighted-average number of outstanding common shares, including the dilutive effect of stock options and convertible securities. (A key metric for shareholder value, showing profitability on a per-share basis.)

Operating Earnings

Profit generated from a company's normal business operations, before interest and taxes. (Measures the profitability of core business activities.)

Foreign Currency Translation Adjustments

Gains or losses that arise when a company translates the financial statements of its foreign subsidiaries into its reporting currency. (Can significantly impact reported financial results, especially for multinational corporations like Abbott.)

Year-Over-Year Comparison

Abbott Laboratories demonstrated robust top-line growth in Q3 2025, with net sales increasing by 6.9% year-over-year, driven by strong performance in Medical Devices. While net earnings saw a slight dip in the quarter, year-to-date net earnings show a significant increase of 13.8%, indicating improved profitability over the longer term. A notable shift is the substantial decline in COVID-19 testing revenue, which is being offset by growth in other segments. R&D investment remains a priority, increasing by 5.3% year-to-date, signaling continued focus on innovation.

Filing Documents

• abt-20250930.htm (10-Q) — 1496KB
• q3202510qex311.htm (EX-31.1) — 9KB
• q3202510qex312.htm (EX-31.2) — 9KB
• q3202510qex321.htm (EX-32.1) — 5KB
• q3202510qex322.htm (EX-32.2) — 5KB
• 0001628280-25-047131.txt ( ) — 8689KB
• abt-20250930.xsd (EX-101.SCH) — 47KB
• abt-20250930_cal.xml (EX-101.CAL) — 63KB
• abt-20250930_def.xml (EX-101.DEF) — 276KB
• abt-20250930_lab.xml (EX-101.LAB) — 628KB
• abt-20250930_pre.xml (EX-101.PRE) — 452KB
• abt-20250930_htm.xml (XML) — 1753KB

- Financial Information

Part I - Financial Information Page

Financial Statements and Supplementary Data

Item 1. Financial Statements and Supplementary Data Condensed Consolidated Statement of Earnings 3 Condensed Consolidated Statement of Comprehensive Income 4 Condensed Consolidated Balance Sheet 5 Condensed Consolidated Statement of Shareholders' Investment 6 Condensed Consolidated Statement of Cash Flows 8 Notes to the Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 25

Controls and Procedures

Item 4. Controls and Procedures 31

- Other Information

Part II - Other Information 31

Legal Proceedings

Item 1. Legal Proceedings 31

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32

Exhibits

Item 6. Exhibits 33 Signature 34 2 Table of Contents Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited) (dollars in millions except per share data; shares in thousands) Three Months Ended Nine Months Ended September 30 September 30 2025 2024 2025 2024 Net sales $ 11,369 $ 10,635 $ 32,869 $ 30,976 Cost of products sold, excluding amortization of intangible assets 5,075 4,698 14,397 13,764 Amortization of intangible assets 420 470 1,260 1,413 Research and development 766 713 2,207 2,095 Selling, general and administrative 3,051 2,895 9,203 8,790 Total operating cost and expenses 9,312 8,776 27,067 26,062 Operating earnings 2,057 1,859 5,802 4,914 Interest expense 121 142 373 423 Interest (income) ( 77 ) ( 91 ) ( 230 ) ( 253 ) Net foreign exchange (gain) loss ( 17 ) ( 11 ) ( 35 ) ( 17 ) Other (income) expense, net ( 150 ) ( 121 ) ( 414 ) ( 222 ) Earnings before taxes 2,180 1,940 6,108 4,983 Taxes on earnings 536 294 1,360 810 Net Earnings $ 1,644 $ 1,646 $ 4,748 $ 4,173 Basic Earnings Per Common Share $ 0.94 $ 0.94 $ 2.72 $ 2.39 Diluted Earnings Per Common Share $ 0.94 $ 0.94 $ 2.70 $ 2.38 Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share 1,742,142 1,739,466 1,741,617 1,740,869 Dilutive Common Stock Options 7,219 8,131 7,544 8,565 Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,749,361 1,747,597 1,749,161 1,749,434 Outstanding Common Stock Options Having No Dilutive Effect 1,443 6,905 1,431 6,892 The accompanying notes to the condensed consolidated financial statements are an integral part of this statement. 3 Table of Contents Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Comprehensive Income (Unaudited) (dollars in millions) Three Months Ended Nine Months Ended September 30 September 30 2025 2024 2025 2024 Net Earnings $ 1,644 $ 1,646 $ 4,748 $ 4,173 Foreign currency trans